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Introduction {#s1}
============

Perfluoroalkyl and polyfluoroalkyl substances (PFASs) are persistent man-made chemicals that have been produced since the 1950s. These compounds are characterized by hydrophobicity and oleophobicity and are extensively used in a wide range of consumer and industrial applications, such as surfactants, adhesives, repellents, food packaging, and fire-fighting foams ([@c8]). Some PFASs have a long half-life in human body. For example, the half-life of perfluorooctanoate (PFOA), perfluorooctane sulfonate (PFOS), and perfluorohexanesulfonate (PFHxS) has been estimated at 3.8, 5.4, and 8.5 y, respectively ([@c29]). Although studies have shown a decrease in body burdens of PFOA and PFOS after restriction of usage in some countries since the early 2000s ([@c19]; [@c32]), the production of PFOS and PFOA has continued in China. Human health concerns regarding exposure to low-level PFASs continue.

The toxicity of PFASs has been extensively studied in experimental animals, with developmental toxicity, carcinogenicity, hepatotoxicity, immunotoxicity, and hormonal effects identified as the effects of most concern ([@c22]; [@c23]). PFASs may also interfere with reproductive functions, but epidemiologic studies are still limited and inconsistent. Vélez et al. ([@c35]) reported that exposure to PFOA and PFHxS at the levels found in the general Canada population may reduce fecundity, indicated by increased time to pregnancy (TTP) and risks of infertility. A Danish National Birth Cohort also linked maternal serum concentrations of PFOS and PFOA with subfecundity ([@c13]). In the study conducted by Buck Louis et al. ([@c7]), perfluorooctane sulfonamide (PFOSA) exposure was associated with 18% reduced fecundability {$\text{adjusted}\,\text{odds}\,\text{ratio}\,\text{for}\,\text{fertility} = 0.82$ \[95% confidence interval (CI): 0.71, 0.95\]} albeit only 10% of the samples had PFOSA levels above the detection limit. However, other studies observed no association between PFASs and TTP or subfecundity ([@c3]; [@c37]; [@c40]). It should be pointed out that some studies were retrospective ([@c3]; [@c13]; [@c35]; [@c40]), whereas others were prospective ([@c7]; [@c37]).

In addition, some studies stratified their analysis by parity or focused only on nulliparous women. They found that positive results could only be observed in parous, not nulliparous women ([@c3]; [@c37]; [@c40]). Reverse causality was postulated for this phenomenon ([@c3]). Previous births may result in lower PFAS levels, and parous women with longer TTP would have had more time to reaccumulate PFASs. However, Vélez et al. ([@c36]) argued that adjusting or stratifying on parity is redundant and would cause over-adjustment, as parity is the result, among other factors, of proven fecundability.

Menstruation has long been viewed as a proxy of female fecundity ([@c6]; [@c18]). Dysfunction of menstrual cycle is a major cause of infertility ([@c17]). Irregular and long cycles have been related to lower fecundity ([@c20]; [@c28]). Animal and human evidences suggest that PFASs affect steroidogenesis and hormone levels manifesting in altered menstrual cycles such as prolonged lengths ([@c4]; [@c14]; [@c34]). In animal studies, a 2-wk exposure to PFOS ($10\;{mg}/{kg}$) has been reported to cause persistent diestrus in rats ([@c2]). In mice, the chronic exposure to a low-dose PFOS ($0.1\;{mg}/{kg}/\text{d}$) has also resulted in estrous cyclicity disruption in adult females ([@c14]). A recent epidemiologic study suggested that menstrual cycles may be lengthened in women with the highest serum concentrations of PFOA in comparison to those with the lowest concentrations ([@c27]). But evidence from Asia is still lacking. The objective of this study was to investigate this association in women who attempted to conceive in China.

Methods {#s2}
=======

Study Population {#s2.1}
----------------

To reduce the incidence of birth defects and improve pregnancy outcomes, the Chinese government has been promoting free preconception care nationwide in recent years ([@c42]). Between August 2013 and April 2015, the Shanghai Birth Cohort Study enrolled women who came for the care at two preconception care clinics in Shanghai, China. Included were couples who were at least 20 y of age, registered residents of Shanghai with no plan to move out of Shanghai in the next 2 y, had stopped using contraception, and planned to conceive naturally and give birth in the collaborating hospitals. Women who had tried continuously to conceive spontaneously for more than 1 y without success or had sought medical assistance to conceive were excluded.

At the time of enrollment, the participants were interviewed by a trained research staff regarding demographic and lifestyle characteristics, environmental factors, and reproductive and medical history. Blood samples were collected. A total of 1,182 women were recruited. Some women did not provide blood samples. Thus, only 950 women had complete PFASs exposure data available. The study was approved by the local ethical committees.

Exposure to PFASs {#s2.2}
-----------------

Blood samples were collected from women at the time of their enrollment and then were stored in freezers at $- 80\,{^\circ}C$ until tested. PFASs were measured at the Shanghai Key Laboratory of Children's Environmental Health, China. Altogether, 10 PFASs were analyzed, including PFOA, PFOS, perfluorononanoic acid (PFNA), PFHxS, perfluorodecanoic acid (PFDeA), perfluoroundecanoic acid (PFUA), perfluorobutane sulfonate (PFBS), perfluorododecanoic acid (PFDoA), perfluoroheptanoic acid (PFHpA), and PFOSA.

PFASs concentrations were measured from $100\;\mu L$ of plasma using high-performance liquid chromatography/tandem mass spectrometry (HPLC/MS-MS) (Agilent 1290--6490; Agilent Technologies Inc., USA). After the sample was thawed at 4°C, $100\;\mu L$ of plasma sample was vortexed with $10\;\mu L$ of $50\,\text{ng}/{mL}$ internal standard solution ($13C_{8}–\text{PFOA}$) for 30 sec. Then $150\;\mu L$ of methanol was added before the second vortex. The third vortex was performed after adding $150\;\mu L$ acetonitrile of 1% formic acid. The mixture was sonicated for 20 min and then centrifuged for 10 min at $12,000\,\text{rpm}$. The supernatant was collected and then filtered through a $0.22 - \mu m$ nylon syringe filter into a $1.5–{mL}$ auto-sampler vial. Calibration standards and quality control materials were prepared by spiking blank fetal bovine serum with the standard mixture of the 10 analytes. Carbon-isotope labeled internal standards were added each time before extraction. Lab technicians were blinded to participant information, and the quality control samples were indistinguishable from the plasma samples. The within-batch coefficients of variation for PFASs concentrations ranged from 0.79% to 8.48%, and the interassay CVs from 1.72% to 8.36%.

All samples had PFOA, PFOS, PFNA, PFHxS, PFDeA, and PFUA above the limit of detection (LOD) (PFOA and PFOS: $0.09\,\text{ng}/{mL}$; PFNA, PFHxS, PFDeA, and PFUA: $0.02\,\text{ng}/{mL}$). The other six PFASs were detected in at least 97% of the samples. Any value below the LOD was assigned half of the LOD.

Outcome {#s2.3}
-------

Women were queried concerning their menstrual cycle characteristics in the past year. The following question was used to assess menstrual cycle characteristics "Is your menstrual cycle regular, i.e., variations month by month within 7 d?" If the answer was "No," then "What were the longest and shortest menstrual cycles in the past year?" Specific numbers of days were recorded. If the answer was "Yes," then ask, "What is the average length of menstrual cycle in the past year?" As to the amount of menstrual bleeding, women were given four choices: light, average, heavy, very heavy. "Light" was considered as hypomenorrhea, while "heavy and very heavy" as menorrhagia in this study. An irregular cycle was defined as variations in length for more than 7 d between cycles ([@c15]). A short cycle was defined as less than 21 d, whereas a long cycle was more than 35 d, based on the Federation Internationale of Gynecologie and Obstetrigue (FIGO) classification ([@c15]). Incomplete information on menstrual characteristics occurred in 2% of the women.

Statistical Analysis {#s2.4}
--------------------

The association between PFASs exposure and menstrual regularity was analyzed using a multiple logistic regression model. PFASs concentrations were treated as a continuous variable (log transformed) as well as categorized into quartiles, with the lowest quartile as the reference level. Risks of long and short cycles were evaluated by multinomial logistic regression model, using normal cycles (defined as cycle length between 21 and 35 d) as the reference. ORs for hypomenorrhea and menorrhagia were also calculated in multinomial logistic regression model using normal volume as the control. Potential confounders included current age, BMI, age at menarche, household income, and parity. Education, smoking, and alcohol consumption were also considered but not included in the final models because they had little impact on the estimated associations. The prevalence of smoking (1.6%) and alcohol consumption (3.7%) were very low in the study population. We categorized women missing a value on income as a new group ($\text{group} = 0$) and imputed age at menarche using the mean value. Current age, age at menarche, and BMI were entered as continuous variables in the adjusted regression model. All outcome estimates are presented as crude and adjusted ORs with 95% CIs. All analyses were performed using SAS 9.2 software (SAS Institute Inc., Cary, NC, USA).

Results {#s3}
=======

Characteristics of the 950 study participants are shown in [Table 1](#t1){ref-type="table"}. The median age at the time of recruitment was 30 y; 91% were nulliparous. Most of women had normal weight with the median BMI of $20.5{\,{kg}/m}^{2}$. The median age at menarche was 13 y. The prevalence of irregular cycles ($\text{variation} \geq 7\,\text{d}$) was 20.1% (190/947). One and one-half percent (14/938) of women had a menstrual cycle length of $< 21\,\text{d}$, whereas 20.1% (189/938) had lengths $> 35\,\text{d}$. The prevalence of menorrhagia and hypomenorrhea were 6.7%(63/947) and 8.0% (76/947), respectively. There was no significant difference in demographic characteristics between those with and without PFAS information (see Table S1).

###### 

Characteristics of the preconception women in Shanghai, China ($n = 950$), 2013--2015.

Table 1 lists characteristics in the first column; the corresponding median values (p25; p75) or n values (percent) are listed in the other columns.

  Characteristics                    Median (p25, p75) or $n$ (%)
  --------------------------------- ------------------------------
  Age (years)                                30 (28, 32)
  Missing                                      10 (1.1)
  Age at menarche (years)                    13 (13, 14)
  Missing                                     143 (15.1)
  Parity                                           
   Nulliparous                                859 (91.0)
   Parous                                      85 (9.0)
   Missing                                     6 (0.6)
   BMI(${{kg}/m}^{2}$)                    20.5 (19.1, 22.5)
   Missing                                     13 (1.4)
  Income ($10^{3}\text{CNY}$)                      
   $< 10$                                      67 (7.5)
   10--15                                     155 (17.3)
   15--30                                     503 (56.2)
   $> 30$                                     170 (19.0)
   Missing                                     55 (5.8)
   Irregular cycle                            190 (20.1)
   Missing                                     3 (0.3)
   Short cycle ($< 21\,\text{d}$)              14 (1.5)
   Long cycle ($> 35\,\text{d}$)              189 (20.1)
   Missing                                     12 (1.3)
   Menorrhagia                                 63 (6.7)
   Hypomenorrhea                               76 (8.0)
   Missing                                     3 (0.3)

The median serum concentrations of PFOA, PFOS, PFNA, and PFHxS were 13.8, 10.5, 1.4, and $0.69\,\text{ng}/{mL}$, respectively ([Table 2](#t2){ref-type="table"}).

###### 

Plasma concentrations of PFASs (ng/mL) in preconception women in Shanghai, China, 2013--2015.

Table 2 lists PFASs in the first column; the corresponding values for LOD, percent greater than LOD, 5th percentile, 25th percentile, median, 75th percentile, and 95th percentile are listed in the other columns.

  PFASs ($n = 950$)   LOD (ng/mL)   $\text{Percent} > \text{LOD}$ (%)   5th Percentile   25th Percentile   Median   75th Percentile   95th Percentile
  ------------------- ------------- ----------------------------------- ---------------- ----------------- -------- ----------------- -----------------
  PFOA                0.09          100                                 6.58             10.08             13.84    18.83             31.85
  PFOS                0.09          100                                 4.38             7.55              10.49    15.37             30.38
  PFNA                0.02          100                                 0.72             1.04              1.36     1.85              3.17
  PFHxS               0.02          100                                 0.45             0.56              0.69     0.88              1.46
  PFDeA               0.02          100                                 0.52             0.91              1.31     1.92              3.95
  PFUA                0.02          100                                 0.54             0.85              1.18     1.63              2.95
  PFBS                0.009         98.9                                0.21             0.23              0.24     0.27              0.32
  PFDoA               0.05          99.9                                0.12             0.16              0.20     0.27              0.41
  PFHpA               0.03          99.4                                0.15             0.18              0.22     0.27              0.49
  PFOSA               0.12          98.2                                0.20             0.21              0.21     0.22              0.23

Note: PFBS, perfluorobutane sulfonate; PFDeA, perfluorodecanoic acid; PFDoA, perfluorododecanoic acid; PFHpA, perfluoroheptanoic acid; PFHxS, perfluorohexanesulfonate; PFNA, perfluorononanoic acid; PFOA, perfluorooctanate; PFOS, perfluorooctane sulfonate; PFOSA, perfluorooctane sulfonamide; PFUA, perfluoroundecanoic acid.

We observed statistically significant associations between PFOA, PFOS, PFNA, and PFHxS exposure and menstrual cycle characteristics ([Tables 3](#t3){ref-type="table"} and [4](#t4){ref-type="table"}). On the other hand, no meaningful relationships were found between the other six PFASs (PFBS, PFHpA, PFDeA, PFUA, PFOSA, PFDoA) and menstrual cycle characteristics. Thus, we present detailed results only in the former four PFASs; the rest are shown in Tables S2--S6.

###### 

Associations between PFASs (ng/mL) and irregular and long cycles in preconception women in Shanghai, China, 2013--2015.

Table 3 lists PFASs in the first column; the corresponding n values, crude OR values (95 percent confidence interval), and adjusted OR values (95 percent confidence interval) for irregular cycle and long cycle are listed in the other columns separately.

  PFASs                                            Irregular cycle       Long cycle                                                    
  ------------------------------------------------ ----------------- ------------------- ------------------- ----- ------------------- -------------------
  PFOA                                                                                                                                           
   Continuous[^*b*^](#t3n2){ref-type="table-fn"}   947                1.34 (0.97, 1.85)   1.52 (1.08, 2.15)  924    1.38 (1.00, 1.92)   1.50 (1.06, 2.10)
   Q1 ($\leq 10.08$)                               238                       ref                 ref         231           ref                 ref
   Q2 (10.08--13.84)                               236                1.67 (1.04, 2.66)   1.71 (1.05, 2.78)  231    1.49 (0.93, 2.38)   1.50 (0.92, 2.42)
   Q3 (13.84--18.83)                               236                1.32 (0.82, 2.14)   1.34 (0.81, 2.22)  231    1.20 (0.74, 1.94)   1.21 (0.73, 1.99)
   Q4 ($> 18.83$)                                  237                1.70 (1.07, 2.70)   1.99 (1.22, 3.24)  231    1.76 (1.11, 2.79)   1.95 (1.21, 3.14)
  PFOS                                                                                                                                           
   Continuous[^*b*^](#t3n2){ref-type="table-fn"}   947                1.26 (0.97, 1.63)   1.29 (0.98, 1.70)  924    1.32 (1.01, 1.71)   1.34 (1.02, 1.75)
   Q1 ($\leq 7.55$)                                238                       ref                 ref         230           ref                 ref
   Q2 (7.55--10.49)                                237                0.85 (0.53, 1.36)   0.93 (0.57, 1.51)  235    1.03 (0.65, 1.65)   1.11 (0.69, 1.80)
   Q3 (10.49--15.37)                               236                1.24 (0.80, 1.94)   1.27 (0.80, 2.03)  230    1.21 (0.77, 1.92)   1.30 (0.81, 2.08)
   Q4 ($> 15.37$)                                  236                1.24 (0.80, 1.94)   1.32 (0.83, 2.09)  229    1.38 (0.88, 2.17)   1.44 (0.90, 2.30)
  PFNA                                                                                                                                           
   Continuous[^*b*^](#t3n2){ref-type="table-fn"}   947                1.37 (0.98, 1.91)   1.50 (1.03, 2.07)  924    1.42 (1.01, 1.99)   1.49 (1.05, 2.11)
   Q1 ($\leq 1.04$)                                234                       ref                 ref         232           ref                 ref
   Q2 (1.04--1.36)                                 242                1.27 (0.79, 2.03)   1.24 (0.76, 2.02)  230    1.31 (0.82, 2.10)   1.36 (0.84, 2.22)
   Q3 (1.36--1.85)                                 233                1.34 (0.84, 2.12)   1.38 (0.85, 2.23)  235    1.38 (0.86, 2.20)   1.48 (0.92, 2.40)
   Q4 ($> 1.85$)                                   238                1.52 (0.96, 2.40)   1.60 (0.99, 2.58)  227    1.59 (1.00, 2.53)   1.67 (1.03, 2.70)
  PFHxS                                                                                                                                          
   Continuous[^*b*^](#t3n2){ref-type="table-fn"}   947                1.66 (1.10, 2.51)   1.80 (1.17, 2.77)  924    1.65 (1.08, 2.50)   1.73 (1.13, 2.65)
   Q1 ($\leq 0.56$)                                235                       ref                 ref         230           ref                 ref
   Q2 (0.56--0.69)                                 240                1.50 (0.91, 2.46)   1.41 (0.84, 2.35)  235    1.44 (0.87, 2.38)   1.35 (0.81, 2.25)
   Q3 (0.69--0.88)                                 232                2.12 (1.31, 3.43)   2.16 (1.31, 3.57)  228    2.24 (1.39, 3.62)   2.24 (1.37, 3.66)
   Q4 ($> 0.88$)                                   240                2.06 (1.28, 3.34)   2.14 (1.30, 3.51)  231    2.05 (1.27, 3.33)   2.08 (1.27, 3.40)

Note: Irregular cycle is defined as $\geq 7\,\text{d}$ of variation. Long cycle is defined as $> 35\,\text{d}$ and is compared with a normal cycle (21--35 d) as reference (ref).

Adjusted for age (continuous), BMI (continuous), income (categorical), age at menarche (continuous) and parity (categorical).

Log-transformed PFASs as continuous variables.

###### 

Associations between PFASs (ng/mL) and menorrhagia and hypomenorrhea in preconception women in Shanghai, China, 2013--2015.

Table 4 lists PFASs in the first column; the corresponding n values, crude OR values (95 percent confidence interval), and adjusted OR values (95 percent confidence interval) for menorrhagia and hypomenorrhea are listed in the other columns separately.

  PFASs                                            Menorrhagia      Hypomenorrhea                                                  
  ------------------------------------------------ ------------- ------------------- ------------------- ----- ------------------- -------------------
  PFOA                                                                                                                                       
   Continuous[^*b*^](#t4n2){ref-type="table-fn"}   871            0.41 (0.23, 0.70)   0.37 (0.21, 0.65)  884    1.45 (0.91, 2.32)   1.40 (0.85, 2.28)
   Q1 ($\leq 10.08$)                               227                   ref                 ref         213           ref                 ref
   Q2 (10.08--13.84)                               216            0.65 (0.34, 1.25)   0.61 (0.31, 1.19)  219    1.75 (0.81, 3.76)   1.84 (0.82, 4.11)
   Q3 (13.84--18.83)                               211            0.62 (0.32, 1.21)   0.61 (0.31, 1.19)  222    2.44 (1.17, 5.06)   2.68 (1.24, 5.78)
   Q4 ($> 18.83$)                                  217            0.27 (0.11, 0.64)   0.21 (0.08, 0.52)  230    1.75 (0.82, 3.74)   1.73 (0.77, 3.86)
  PFOS                                                                                                                                       
   Continuous[^*b*^](#t4n2){ref-type="table-fn"}   871            0.56 (0.36, 0.86)   0.57 (0.37, 0.90)  884    1.05 (0.71, 1.54)   1.05 (0.70, 1.57)
   Q1 ($\leq 7.55$)                                223                   ref                 ref         208           ref                 ref
   Q2 (7.55--10.49)                                218            0.38 (0.19, 0.75)   0.38 (0.19, 0.77)  225    1.19 (0.59, 2.40)   1.15 (0.56, 2.36)
   Q3 (10.49--15.37)                               214            0.38 (0.19, 0.77)   0.39 (0.19, 0.78)  224    1.40 (0.71, 2.78)   1.33 (0.66, 2.68)
   Q4 ($> 15.37$)                                  216            0.28 (0.13, 0.60)   0.29 (0.13, 0.62)  227    1.24 (0.62, 2.50)   1.21 (0.59, 2.48)
  PFNA                                                                                                                                       
   Continuous[^*b*^](#t4n2){ref-type="table-fn"}   871            0.50 (0.28, 0.89)   0.47 (0.26, 0.86)  884    1.57 (0.97, 2.54)   1.58 (0.95, 2.63)
   Q1 ($\leq 1.04$)                                228                   ref                 ref         214           ref                 ref
   Q2 (1.04--1.36)                                 214            0.77 (0.40, 1.48)   0.74 (0.38, 1.44)  218    2.43 (1.09, 5.43)   2.38 (1.05, 5.40)
   Q3 (1.36--1.85)                                 213            0.58 (0.29, 1.18)   0.53 (0.25, 1.10)  227    3.07 (1.41, 6.70)   2.90 (1.31, 6.41)
   Q4 ($> 1.85$)                                   216            0.43 (0.20, 0.93)   0.41 (0.19, 0.90)  225    2.10 (0.93, 4.75)   2.05 (0.89, 4.73)
  PFHxS                                                                                                                                      
   Continuous[^*b*^](#t4n2){ref-type="table-fn"}   871            0.18 (0.07, 0.43)   0.14 (0.06, 0.36)  884    1.78 (0.99, 3.21)   1.72 (0.93, 3.19)
   Q1 ($\leq 0.56$)                                226                   ref                 ref         207           ref                 ref
   Q2 (0.56--0.69)                                 220            0.69 (0.36, 1.29)   0.65 (0.34, 1.23)  225    3.25 (1.37, 7.75)   3.53 (1.46, 8.53)
   Q3 (0.69--0.88)                                 213            0.42 (0.20, 0.87)   0.42 (0.20, 0.87)  222    2.83 (1.17, 6.84)   2.44 (0.99, 6.04)
   Q4 ($> 0.88$)                                   212            0.30 (0.13, 0.68)   0.26 (0.11, 0.61)  230    3.64 (1.55, 8.58)   3.59 (1.50, 8.60)

Note: ref, reference.

Adjusted for age (continuous), BMI (continuous), income (categorical), age at menarche (continuous) and parity (categorical).

Log-transformed PFASs as continuous variables.

Irregular Menstrual Cycle {#s3.1}
-------------------------

[Table 3](#t3){ref-type="table"} presents that most PFASs exposures were positively associated with irregular menstrual cycle, and the associations with PFOA, PFNA, and PFHxS levels were statistically significant. In the adjusted model, a log-unit increase in PFOA, PFNA, and PFHxS was associated with significantly increased odds of self-reported history of irregular menstrual cycle by 52%, 50%, 80%, respectively \[$\text{PFOA}\,\text{OR} = 1.52$ (95% CI: 1.08, 2.15); $\text{PFNA}\,\text{OR} = 1.50$ (95% CI: 1.03, 2.07); $\text{PFHxS}\,\text{OR} = 1.80$ (95% CI: 1.17, 2.77)\]. The strongest association was shown with PFHxS. After categorization of exposure levels into quartiles, elevated risk estimates for irregular cycles were observed at almost all levels of these three chemicals ([Table 3](#t3){ref-type="table"}).

Long and Short Menstrual Cycles {#s3.2}
-------------------------------

There were significant positive associations between PFOA, PFOS, PFNA, and PFHxS concentrations and self-reported long menstrual cycles according to the adjusted multivariable logistic regression models \[$\text{PFOA}\,\text{OR} = 1.50$ (95% CI: 1.06, 2.10); $\text{PFOS}\,\text{OR} = 1.34$ (95% CI: 1.02, 1.75); $\text{PFNA}\,\text{OR} = 1.49$ (95% CI: 1.05, 2.11); $\text{PFHxS}\,\text{OR} = 1.73$ (95% CI: 1.13, 2.65)\] ([Table 3](#t3){ref-type="table"}). PFHxS also showed the strongest association with long cycles. In the models including quartiles of chemicals, elevated risk estimates for long cycles were observed at all levels of these four substances. Owing to few women with short cycles ($n = 14$), no significant association was found between PFASs exposure and short cycles (see Table S4).

Menorrhagia and Hypomenorrhea {#s3.3}
-----------------------------

[Table 4](#t4){ref-type="table"} shows that each log-unit increase in PFOA, PFOS, PFNA, and PFHxS exposure was associated with decreased odds of self-reported menorrhagia \[$\text{PFOA}\,\text{OR} = 0.37$ (95% CI: 0.21, 0.65); $\text{PFOS}\,\text{OR} = 0.57$ (95% CI: 0.37, 0.90); $\text{PFNA}\,\text{OR} = 0.47$ (95% CI: 0.26, 0.86); $\text{PFHxS}\,\text{OR} = 0.14$ (95% CI: 0.06, 0.36)\]. Conversely, increasing PFOA, PFNA, and PFHxS levels were associated with higher odds of self-reported history of hypomenorrhea in certain categories. No significant associations were found between PFOS exposure and hypomenorrhea.

Discussion {#s4}
==========

Our study found that increased exposure to PFOA, PFOS, PFNA, and PFHxS was associated with higher odds of irregular and long menstrual cycle and lower risks of menorrhagia in women who plan to be pregnant. In contrast, women with higher levels of PFOA, PFNA, and PFHxS were more likely to have hypomenorrhea.

Two previous studies have evaluated the association between PFOA and PFOS and menstrual irregularity and length. Our results are consistent with those reported in a subset of 1,240 pregnant women randomly selected from the Danish National Birth Cohort ([@c13]). They found that the risk of irregular menstrual cycle was higher in women exposed to PFOA (15.0% in the upper three quartiles vs. 9.0% in the lowest quartile) and PFOS (14.2% in the upper three quartiles vs. 11.6% in the lowest quartile) ([@c13]). The INUENDO cohort enrolled 1,623 pregnant women in three countries (Greenland, Poland, and Ukraine) ([@c27]) and found that PFOA exposure levels were positively associated with long menstrual cycles. The OR of long periods was 1.8 (95% CI: 1.0, 3.3) when comparing the highest tertile of exposure level with the lowest. Although no significant associations were found between PFOS exposure levels and cycle irregularity and length, there appeared to be a tendency for more irregular cycles with higher PFOS exposure \[$\text{OR} = 1.7$ (95% CI: 0.8, 3.5)\].

Although still scarce, experimental animal studies have consistently observed estrous cyclicity disruption and prolongation with increased PFASs exposure. Austin et al. found that the administration of high-dose PFOS ($10\;{mg}/{kg}$) for 2 wk could cause a persistent diestrus in rats, whereas the doses of $1\;{mg}/{kg}$ did not ([@c2]). Another animal study examined the influence of chronic exposure to a low-dose PFOS ($0.1\;{mg}/{kg}/\text{d}$) on female reproductive function and showed that adult female mice exposed to PFOS for 4 mo had a prolongation of diestrus without signs of toxic effects. Serum estrogen ($E_{2}$) and progesterone levels at proestrus and diestrus were reduced, and a luteinizing hormone (LH) surge did not emerge at proestrus ([@c14]). Previous *in vivo* and *in vitro* studies on rats also found a negative relationship between PFOA and testosterone level ([@c5]; [@c25]). This may lead to deficits in the follicular development and ovulation, and, consequently, irregularity and prolongation of diestrus. To our knowledge, no experimental animal studies were conducted on other PFASs in this area.

Thyroid dysfunction could be another endocrine target for PFASs. Mounting evidence from animal ([@c9]; [@c24]; [@c26]; [@c33]) and human studies ([@c11]; [@c39]) showed decreased levels of thyroid hormones at higher PFASs concentrations. For example, rats treated with PFOS were found to have decreased thyroxine ($T_{4}$) and triiodothyronine ($T_{3}$), without an expected increase in thyroid stimulating hormone (TSH) ([@c9]). A prospective cohort study demonstrated that pregnant women with higher PFHxS levels had elevated TSH levels ([@c39]). Exposure to PFNA, perfluorododecanoic acid (PFDoDA) and perfluoroundecanoic acid (PFUnDA) were also associated with lower free $T_{4}$ and total $T_{4}$ levels ([@c39]). These findings suggest that PFASs are associated with hypothyroidism. Because the hypothalamic--pituitary--ovarian axis (HPO) and the hypothalamic--pituitary--thyroid axis (HPT) are physiologically related and act together as a unified system, both hyper- and hypothyroidism may result in menstrual disturbances ([@c12]). In women, hypothyroidism usually is associated with abnormal menstrual cycles characterized mainly by altered ovulatory function, menstrual irregularities, and subfertility ([@c10]).

Compared with previous epidemiologic studies, the main strength of the present study was that the study population was restricted to pre-pregnant women planning to conceive and that their blood samples were collected before pregnancy. Because the concentration of PFASs may decline in pregnancy due to blood volume expansion, decreased serum albumin concentration, changes in PFAS pharmacokinetics during pregnancy, and placental transfer of PFASs to the fetus ([@c1]; [@c16]; [@c33]), prepregnancy PFAS concentrations reflect true exposure levels.

In addition, a recent study reported that the prevalence of irregular cycle, menorrhagia, and hupomenorrehea in Chinese nurses with nonshift work was 14.9%, 9.6% and 7.2%, respectively ([@c38]). The corresponding prevalence in our study was 20.1%, 6.7%, and 8.0%, respectively. Thus, the various cycle characteristics in our study are similar to those reported in other studies in China.

Our studies also have deficiencies. The amount of menstrual bleeding reported by the women (less than average, average, more than average, and excessive) is rather subjective. Misclassifications of that variable are likely. However, it is unlikely that the misclassifications are related to PFAS levels. Thus, the nondifferential misclassification may have drawn the results toward the null. Second, we excluded women who had difficulties in conception. Our study was actually a prospective cohort study, though the current analysis was cross-sectional in nature. After a 1-y follow-up, approximately 20% of women remained nonpregnant (J. Zhang, unpublished data, 2017), indicating that our study population was similar to the general population. Third, considering the low prevalence of short cycles (1.5%, 14/938), we did not have enough statistical power to examine the association between PFAS level and short cycles. Fourth, information on menstrual cycle characteristics in the past 12 mo was collected retrospectively. Several studies have compared the retrospectively with prospectively collected information on menstrual cycle and observed a moderate agreement on menstrual cycle length with correlation coefficients ranging from 0.45 to 0.50 ([@c21]; [@c31]). Small et al. ([@c31]) found that women who were married and trying to become pregnant were more likely to have accurate self-reported menstrual cycle information ([@c31]). Thus, it is possible that self-reported information in our study is more accurate given that all of them were married and planning to be pregnant. Furthermore, this misclassification due to recall errors was likely to be nondifferential because all women were unaware of their level of PFAS burden.

Finally, this was a cross-sectional analysis. The causality remains uncertain. Literature shows that men have a higher level of PFASs than women. Physiologically based pharmacokinetic modeling estimated that up to 30% of the difference between men and women may be attributable to menstruation, indicating that menstruation might be an important elimination pathway for PFASs in women ([@c41]). Thus, it is possible that the association between higher PFAS levels and lighter menstrual flow and irregular or longer cycles might be a reverse causality due to less menstruation. On the other hand if this is true, we would expect that most PFAS levels would be affected. Moreover, animal studies have demonstrated disrupted estrous cycles after PFOS exposure ([@c2]; [@c14]). Further prospective studies are needed to verify the association between PFASs concentration and menstrual cycle in women.

Conclusions {#s5}
===========

Certain PFASs exposure at the environment-relevant dose is associated with self-reported menstrual cycle irregularity, longer length, and less bleeding volume. Due to the ubiquity of PFASs and the critical role of menstrual cycle in fecundity, our findings may have important public health implications.
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